Trademark: 90182575
Word
PIRLIFDI
Status
Pending
Status Code
734
Status Date
Friday, April 5, 2024
Serial Number
90182575
Mark Type
4000
Filing Date
Tuesday, September 15, 2020
Published for Opposition
Tuesday, September 14, 2021

Trademark Owner History
Bristol-Myers Squibb Company - Owner At Publication

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing
The word(s) "PIRLIFDI" has no meaning in a foreign language.

Trademark Events
Apr 6, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 5, 2024
Sou Extension 5 Granted
Apr 5, 2024
Sou Extension 5 Filed
Apr 5, 2024
Sou Teas Extension Received
Oct 14, 2023
Notice Of Approval Of Extension Request E-Mailed
Oct 12, 2023
Sou Extension 4 Granted
Oct 12, 2023
Sou Extension 4 Filed
Oct 12, 2023
Sou Teas Extension Received
Aug 2, 2023
Teas Change Of Correspondence Received
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Owner Address Received
Apr 28, 2023
Notice Of Approval Of Extension Request E-Mailed
Apr 26, 2023
Sou Extension 3 Granted
Apr 26, 2023
Sou Extension 3 Filed
Apr 26, 2023
Sou Teas Extension Received
Nov 4, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 2, 2022
Sou Extension 2 Granted
Nov 2, 2022
Sou Extension 2 Filed
Nov 2, 2022
Sou Teas Extension Received
May 7, 2022
Notice Of Approval Of Extension Request E-Mailed
May 5, 2022
Sou Extension 1 Granted
May 5, 2022
Sou Extension 1 Filed
May 5, 2022
Sou Teas Extension Received
Nov 9, 2021
Noa E-Mailed - Sou Required From Applicant
Sep 14, 2021
Official Gazette Publication Confirmation E-Mailed
Sep 14, 2021
Official Gazette Publication Confirmation E-Mailed
Sep 14, 2021
Official Gazette Publication Confirmation E-Mailed
Sep 14, 2021
Published For Opposition
Aug 26, 2021
Notification Of Notice Of Publication E-Mailed
Aug 26, 2021
Notification Of Notice Of Publication E-Mailed
Aug 26, 2021
Notification Of Notice Of Publication E-Mailed
Aug 5, 2021
Approved For Pub - Principal Register
Aug 5, 2021
Examiner's Amendment Entered
Aug 5, 2021
Notification Of Examiners Amendment E-Mailed
Aug 5, 2021
Examiners Amendment E-Mailed
Aug 5, 2021
Examiners Amendment -Written
Jul 28, 2021
Teas/Email Correspondence Entered
Jul 27, 2021
Correspondence Received In Law Office
Jul 27, 2021
Teas Response To Office Action Received
Jan 29, 2021
Notification Of Non-Final Action E-Mailed
Jan 29, 2021
Non-Final Action E-Mailed
Jan 29, 2021
Non-Final Action Written
Jan 27, 2021
Assigned To Examiner
Oct 22, 2020
New Application Office Supplied Data Entered
Sep 18, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24